title: Addition of trimethoprim-sulfamethoxazole to ceftazidime during parenteral treatment of melioidosis is not associated with a long-term outcome benefit.
authors.forename: Wirongrong
authors.initials: W
authors.lastname: Chierakul
authors.forename: Siriluck
authors.initials: S
authors.lastname: Anunnatsiri
authors.forename: Wipada
authors.initials: W
authors.lastname: Chaowagul
authors.forename: Sharon J
authors.initials: SJ
authors.lastname: Peacock
authors.forename: Ploenchan
authors.initials: P
authors.lastname: Chetchotisakd
authors.forename: Nicholas P
authors.initials: NP
authors.lastname: Day
mesh_terms: D002442:Ceftazidime / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007263:Infusions, Parenteral; D008554:Melioidosis / Q000188:drug therapy*; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D002442:Ceftazidime